Narrow Results

Regarding diagnosis, treatment, monitoring, and prognosis, nanomedicine will play a critical role in customized medicine in the future. Nanomedicine allows for better targeting, more accurate disease mapping, and fewer side effects by delivering drugs straight to the sick cells. The advantageous alterations that nanotechnology makes to the physiochemical, mechanical, magnetic, electrical, and optical properties of computing materials enable the development of new and innovative products. Food security, processing, coloring, nutritional absorption, flavor, nutrition, delivery, disease detection, food functioning, environmental protection, and cost-effective storage and distribution are a few of the important links between nanotechnology and food systems. Nanomaterials are used in biofuel production, wastewater treatment, biosensor pollution removal tools, photocatalysts, biomedical imaging and cancer treatments, and wearable chemical and environmental sensors, as shown by a number of academic publications. A few of the main challenges facing the application of nanotechnology are scalability, increased production rates, managing unwanted byproducts, repeatability and quality control of nanomaterials, and enhanced manufacturing rates.

Competitive Positioning Strategies for Australian Biotech Companies A Road Map to Achieve Competitive Position in the Global Biotech Marketplace Part III — Australia: Current Position and Key Success Factors.

This article discusses about the importance of research and development in Australia especially agricultural sector. It touches on the funding of livestock biotech research and development.

Kissei Pharma Collaborates with JCR Pharmaceuticals.

Japan's Bioventure Today—SymBio Pharmaceuticals Limited.

Ranbaxy Laboratories Limited (RLL) Collaborates with Medicines for Malaria Venture (MMV).

Roche Grants Tamiflu sublicense to Indian Company.

US-based Stem Cell Co Ties Up with LifeCell to Set up Indian Subsidiary.

Moleac: Flowing Therapeutics from the East to the West and Expertise from the West to the East.

ADDF Supports Axxam to Develop Therapeutics for Alzheimer's.

Epitomics Signs Agreement with Bayer for Antibody Technology.

Sirnaomics Partners Guangdong Zhongsheng to Dvelop siRNA Therapeutics.

Jubilant, Endo Achieve Late Stage Discovery Milestone.

Merck and Hanwha Chemical Corporation Establish Global Strategic Collaboration for Biosimilar.

SIOGEN Awarded 'Most Innovative Biotech in Asia'.

GENEWIZ, Inc. and Biomatters Announce Strategic Partnership to Align DNA-Based Services and Analysis Software.

Invida Launches Atopiclair^TM, a Treatment for Atopic Dermatitis Symptoms.

Accenture Implements Nationwide Electronic Health Record System in Singapore.

A*STAR & Olympus Singapore Establish Microscopy Suite to Study Human Diseases at the Nano-level.

INDIA – Bioven starts BV-NSCLC-001 Phase III trial in NSCLC.

INDIA – Initiative in Chemical Biology and Therapeutics.

PHILLIPPINES – Asia–Pacific Analysis: The slow road to green energy.

SINGAPORE – Takeda progressing well in Asia with New Drug Applications.

SINGAPORE – NTU and University of Warwick boost brainpower in global neuroscience research.

THAILAND – Thai PhD. student awarded Monsanto's Beachell–Borlaug International Scholarship for rice improvement research.

EUROPE – Open access will change the world, if scientists want it to.

UNITED STATES & CANADA – Verisante places Aura Beta Units for safety, verification testing in B.C., Alberta and Ontario clinics.

UNITED STATES & CANADA – Life Technologies sets new worldwide standard for criminal forensic testing with introduction of GlobalFilerTM Express Kit.

UNITED STATES & CANADA – How immune cells can nudge nerves to regrow.

UNITED STATES & CANADA – Improved Genomic Target Selection Using IDT Oligos.

UNITED STATES & CANADA – US team uncover non-invasive method for diagnosing epilepsy.

Thermo Fisher Scientific and Applikon Biotechnology sign bilateral supply agreement.

AET BioTech and BioXpress Therapeutics to co-develop biosimilar Adalimumab.

Octa Phillip Bioscience Managers announces first close on new healthcare fund.

Agilent Technologies' and PREMIER Biosoft's platforms work together to advance lipidomics research.

Phosphagenics licenses TPM^® platform to Indian pharmaceutical company.

Dr. Louis-Philippe Vézina, named as a recipient of the 2012 Prix du Quebec.

INDIA – Ozone eating away Indian crop yields.

INDIA – Polio shots better than oral drops, says study.

JAPAN – Natural protein in rice helps keep arsenic out in grains.

THE PHILIPPINES – Philippines adopts inactivated polio vaccine strategy.

SINGAPORE – A*STAR's Institute of Microelectronics and Singapore Biomicro to develop a first-of-its-kind, implantable wireless blood glucose monitoring sensor device.

THAILAND – Ebola-affected countries face new threat: food crisis.

THAILAND – Fending off dengue with insecticide-treated uniforms.

AFRICA – New test to combat major cause of preventable blindness in Africa.

BANGLADESH – Arsenic linked to lung cancer in Bangladesh.

EUROPE – Human-milk-oligosaccharides can protect against noroviruses.

UNITED STATES – Researchers discover possible cause of common dementia.

UNITED STATES – Improved mouse model may accelerate research on potential Ebola vaccines and treatments.

UNITED STATES – New device yields close-up look at metastasis.

UNITED STATES – Scientists research ways to use an organism's own pathway to synthesize potential therapeutics.

RESEARCH HIGHLIGHTS – Quality issues in herbal medicine clinical trials.

A*STAR and GE Healthcare to improve healthcare outcomes through next generation innovations.

Phylogica enters into research and licensing agreement with Genentech.

FUJIFILM Completes Acquisition of Kalon Biotherapeutics.

Bina Technologies acquired by Roche.

ONO and Gilead enter exclusive license agreement to develop BTK inhibitor for the treatment of B-cell malignancies and other diseases.

Uroplasty and Vision-Sciences to merge, creating medical device company.

Amgen joins with LabCentral to support life-sciences and biotech startups in Cambridge.

Temasek Life Sciences Laboratory appoints Prof Yu Hao as Executive Director.

SomaGenics receives $2,275,000 in NIH funding to develop its RNAi Therapeutics and microRNA Technologies.

How the largest birds on Earth and their strong immune systems lead to a breakthrough in antibody technology research.

The following topics are under this section:

• ASIA-PACIFIC — Identification of Therapeutic Points for Genetically Diverse and Fatal Leukaemia
• ASIA-PACIFIC — Novel Microfluidic Processes for Drug Development
• ASIA-PACIFIC — Development of Anti-Microbial Coating against COVID-19
• ASIA-PACIFIC — Partnership between Arcturus Therapeutics and Duke-NUS Medical School to develop COVID-19 Vaccine
• ASIA-PACIFIC — Nanoscopic Insights to Proteins against Huntington’s Disease
• ASIA-PACIFIC — Unravelling the Impact of Marine Heatwave on Coral Reef Fishes
• ASIA-PACIFIC — Regulation of Plant Pores by MicroRNAs
• ASIA-PACIFIC — Discovering Clues to Longevity in Our Genome
• ASIA-PACIFIC — Repurposing Nature’s Products to Viable Materials
• ASIA-PACIFIC — Reverse Conversion of Oestrogens to Androgens
• REST OF THE WORLD — HER2-targeted Antibody Drug Conjugate Shows Promise in Patients with Non-Breast-Gastric Cancers
• REST OF THE WORLD — New Research finds Teeth as a Biological Archive
• REST OF THE WORLD — Finding Treatment for Muscular Dystrophy using CRISPR

The last century has witnessed groundbreaking advances in clinical medicine across the entire diagnostic and therapeutic range, but inequities in access to these advances and innovations continue to be a major challenge to our societies.

Innovations are often initiated by "eureka" moments of discovery, but realising their full potential depend on a process of continuous incremental innovation and interaction involving complex networks. When developing systems that reward, encourage, and sustain medical advances, policy makers must recognise four important factors. First, "incremental" and "continuous" innovation is as important as "breakthrough" innovation. Second, investment across the entire innovation process is needed. Third, the ability of physicians to work across a wide range of scientific fields at "the bench and bedside" is critical to continuous innovation. And fourth, final medical advance that can result from an initial discovery may not be obvious and only occur following interaction with experts and innovations in other fields.

The ability of neural stem cells (NSCs) to home to diseased areas of the brain and their capacity to differentiate into all neural phenotypes provides a powerful tool for the treatment of both diffuse and localized neurologic/oncogenic disorders. NSCs are the most immature neural precursor cells in the nervous system and are defined by their ability to self-renew by symmetric division as well as to give rise to more mature progenitors of all neural lineages by asymmetric division. A full understanding of the molecular mechanisms regulating their migratory properties and their choice between various differentiation programs is essential if these cells are to be used for therapeutic applications. This review focuses on summarizing the factors and signaling molecules that are involved in migration and differentiation of neural stem cells and also gives an insight into therapeutic potential of these cells with an emphasis on glioma therapy.

Feline infectious peritonitis (FIP) is an important disease frequently seen in veterinary practice affecting cats worldwide. The objectives of this review were to provide the updated progress of FIP diagnostics and therapeutics. The diagnosis of FIP is based on age, origin, clinical signs and physical examination of the patient. However, a definitive diagnosis of FIP ante-mortem remains challenging. This review will cover several diagnostic tests with emphasis on PCR-based diagnoses for the disease. Furthermore, there is still no effective treatment for FIP although several approaches have been used to treat cats with FIP. This review will also discuss the effectiveness of antiviral drugs, anti-inflammatory, immunosuppressive drugs, and immunostimulant drugs for FIP treatments.

Heritable breast cancer syndromes have identified the recognition and processing of DNA double strand breaks as a fundamental vulnerability in the breast epithelium. The role of homology-directed DNA repair is particularly prominent, indicating that this repair pathway is rate-limiting. Although the activities of the tumor suppressor genes underlying heritable breast cancer act in a common pathway of DNA double strand break repair, the specific lesions result in surprisingly different patterns of biomarkers in the breast cancers, suggesting that they arise from different cell types that include the luminal, basal and progenitor cells within the breast epithelium. Therefore, each cell type appears to have distinct underlying vulnerabilities in repair of DNA double strand breaks. While the heterogeneity of targets poses a challenge to develop specific therapies, these pathways also render tumor cells sensitive to drugs targeting double strand break repair pathways offering new options for therapies. As double strand break repair is a common pathway underlying breast cancer risk, therapies that enhance the proficiency of this pathway offer a strategy for chemoprevention.

The development of nanoscale delivery vehicles for siRNAs is a current topic of considerable importance. However, little is understood about the exact trafficking mechanisms for siRNA-vehicle complexes across the plasma membrane and into the cytoplasm. While some information can be gleaned from studies on delivery of plasmid DNA, the different delivery requirements for these two vehicles makes drawing specific conclusions a challenge. However, using chemical inhibitors of different endocytosis pathways, studies on which endocytotic pathways are advantageous and deleterious for the delivery of nucleic acid drugs are emerging. Using this information as a guide, it is expected that the future development of effective siRNA delivery vehicles and therapeutics will be greatly improved.

Genomic modification through nucleic acid delivery is a frequently applied method in fundamental biological studies and offers a potent therapeutic strategy for disease treatment and biological research. Delivery of nucleic sequences is therefore an attractive facet of biological nanotechnology as highly specific, efficient, and nonantagonistic delivery is necessary for in vivo and clinical use. Previous vectors have suffered from immunogenic responses, serum dependent inactivation, and cytotoxicity, hindering their translational applicability. Current research in polymeric-based nucleotide delivery strives to offer a highly biocompatible, broad use vector through the utilization of polypeptide and polyamine conjugation that can be easily tailored for specific targeting or wide dissemination. Cross-linking low molecular weight polyamines and lipophilic derivatization for amphiphile creation has lead to improved biocompatibility and transfection efficiency compared to higher molecular weight polyamines. Derivatization of hyperbranched and dendritic polyamido- and polyamines has allowed for the formation of efficient in vivo transfection vectors; ring opening synthesis of N-carboxyanhydride amino acids have led to controlled peptide architectures for improved transfection while simultaneously providing convenient primary amines useful in functionalization. Polymer libraries of poly(ß-amino esters) have provided insights into useful architectures for in vitro and in vivo gene delivery. Grafting small molecules to polyamines, such as folate and galactose, for enhanced interaction with cell surface receptors for selective targeting of specific cell types has proven to be encouraging and remains a prominent aspect in biological nanotechnology.

This review paper presents an overview of periodontal disease, beginning with clinical aspects including prevalence, etiology, disease progression mechanisms and implications for general health, followed by current diagnostic and therapeutic approaches. We then describe experimental models used for in vitro and in vivo investigations of periodontal disease, and emerging therapeutic approaches based on biomedical and tissue engineering concepts, nanotechnology, gene and stem cell therapies. We aim to provide bioengineers, tissue engineers and nanotechnology researchers an overall understanding of the state-of-the-art of periodontal disease to foster technological innovation based on interdisciplinary research and collaboration between physical and medical scientists.

Chemotherapy and other traditional anticancer treatments are losing their efficacy in the battle against cancer. As a result, cancer treatment strategies must be continually adjusted to meet the rising demand for alternative medicines. Several viral and non-viral vectors have been used previously. However, it has been shown that microorganisms are a strong contender for successfully combating cancer. They are a remarkable source of toxins, polysaccharides, tumor-specific anticancer genes, nanodrugs and gene-delivery vectors. One of the emerging key players in cancer therapy is bacteria. It has been demonstrated that traditional methods of altering the microbiome, such as antibiotics, probiotics and microbiota transplants, can sometimes increase the effectiveness of cancer therapies. However, problems with these methods, such as consistency and collateral damage to the commensal microbiota, spur the development of new technologies specifically aimed at the microbiome-cancer interface. In light of nanotechnology’s success in transforming cancer diagnostics and treatment, nanotechnologies with the capacity to control interactions that occur across microscopic and molecular length scales in the microbiome and the tumor microenvironment have the potential to provide innovative methods for cancer treatment. The relationship between nanotechnology, the microbiome and cancer offers tremendous potential. This paper highlights the contributions of significant bacterial groups to several anticancer research fields.